Join the debate on human genome editing!
By Yeyang Su,
Impact Ethics [cites CGS' Marcy Darnovsky]
| 11. 03. 2018
At the end of this month, the Second International Summit on Human Genome Editing will be held in Hong Kong. In the invitation to participants, the local host and President of the Academy of Sciences of Hong Kong, Dr Lap-Chee Tsui takes care to note that: “[o]f particular concern is the possibility of heritable genome editing… and applications for purposes other than to treat disease or disability.”
The possibility of heritable human genome editing is what propelled the United States National Academy of Sciences and National Academy of Medicine, United Kingdom’s Royal Society, and the Chinese Academy of Sciences to co-organize the First International Summit on Human Gene Editing three years ago, in Washington. This Summit was a response to the first published study in human embryos using CRISPR-Cas9 – then a newly discovered genome editing tool characterized by “unprecedented efficiency and stunning ease of use.”The research led by Junjiu Huang and Canquan Zhou at Sun Yat-sen University in Guangzhou, China, aimed to modify the endogenous β-globin gene that causes β-thalassaemia. β-thalassaemia affects about 2% of people in China, ...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...